Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15802800rdf:typepubmed:Citationlld:pubmed
pubmed-article:15802800lifeskim:mentionsumls-concept:C0007450lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0270611lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0917798lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0006772lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0205234lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0669017lld:lifeskim
pubmed-article:15802800lifeskim:mentionsumls-concept:C0205355lld:lifeskim
pubmed-article:15802800pubmed:issue4lld:pubmed
pubmed-article:15802800pubmed:dateCreated2005-4-1lld:pubmed
pubmed-article:15802800pubmed:abstractTextDY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate), a calmodulin antagonist, provides protection against Ca(2+) overload-associated cytotoxicity and brain injury after cerebral ischemia in rats. In this study, we assessed the effect of DY-9760e on ischemic infarct volume in cats subjected to permanent focal cerebral ischemia. DY-9760e was infused for 6 h, beginning 5 min after occlusion of the middle cerebral artery. The infarct volume was measured at the end of drug infusion. DY-9760e, at the dose of 0.25 but not 0.1 mg/kg/h, significantly reduced cerebral infarct volume without affecting any physiological parameters, and its protective effect was mainly evident in the cerebral cortex, where the penumbra, a salvageable zone, exists. The present study demonstrates that DY-9760e protects against brain injury after focal ischemia in a gyrencephalic animal as well as in the rodents reported previously and suggests its therapeutic value for the treatment of acute stroke.lld:pubmed
pubmed-article:15802800pubmed:languageenglld:pubmed
pubmed-article:15802800pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15802800pubmed:citationSubsetIMlld:pubmed
pubmed-article:15802800pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15802800pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15802800pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15802800pubmed:statusMEDLINElld:pubmed
pubmed-article:15802800pubmed:monthAprlld:pubmed
pubmed-article:15802800pubmed:issn0918-6158lld:pubmed
pubmed-article:15802800pubmed:authorpubmed-author:SugimuraMasun...lld:pubmed
pubmed-article:15802800pubmed:authorpubmed-author:FukushiHiromi...lld:pubmed
pubmed-article:15802800pubmed:authorpubmed-author:ShirasakiYasu...lld:pubmed
pubmed-article:15802800pubmed:authorpubmed-author:TakamoriHideo...lld:pubmed
pubmed-article:15802800pubmed:authorpubmed-author:KanazawaYoshi...lld:pubmed
pubmed-article:15802800pubmed:authorpubmed-author:KitanoYutakaYlld:pubmed
pubmed-article:15802800pubmed:issnTypePrintlld:pubmed
pubmed-article:15802800pubmed:volume28lld:pubmed
pubmed-article:15802800pubmed:ownerNLMlld:pubmed
pubmed-article:15802800pubmed:authorsCompleteYlld:pubmed
pubmed-article:15802800pubmed:pagination629-33lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:meshHeadingpubmed-meshheading:15802800...lld:pubmed
pubmed-article:15802800pubmed:year2005lld:pubmed
pubmed-article:15802800pubmed:articleTitleDY-9760e, a calmodulin antagonist, reduces brain damage after permanent focal cerebral ischemia in cats.lld:pubmed
pubmed-article:15802800pubmed:affiliationNew Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan. shiram8s@daiichipharm.co.jplld:pubmed
pubmed-article:15802800pubmed:publicationTypeJournal Articlelld:pubmed